This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Biotech Stock Roundup: ACAD Down on CRL, EBS Gets Additional Order & Other Updates
by Zacks Equity Research
The biotech sector was in focus last week with regulatory updates from Acadia (ACAD) and vaccine updates from quite a few companies like Emergent (EBS), among others.
Biotech Stock Roundup: ACAD Down on CRL, EBS Gets Additional Order & Other Updates
by Zacks Equity Research
The biotech sector was in focus last week with regulatory updates from Acadia (ACAD) and vaccine updates from quite a few companies like Emergent (EBS), among others.
ACADIA (ACAD) Gets CRL From FDA for Nuplazid sNDA, Shares Down
by Zacks Equity Research
The FDA issues a Complete Response Letter to ACADIA's (ACAD) sNDA for Nuplazid (pimavanserin) for treating hallucinations and delusions associated with dementia-related psychosis. Stock falls.
Why Is Acadia (ACAD) Down 45% Since Last Earnings Report?
by Zacks Equity Research
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Moving Average Crossover Alert: ACADIA Pharma
by Zacks Equity Research
ACADIA Pharmaceuticals (ACAD) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
Biotech Stock Roundup: AMGN's Acquisition, ACAD's Regulatory Update & More
by Zacks Equity Research
The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Amgen (REGN), Acadia (ACAD) and Gilead (GILD).
ACADIA (ACAD) Falls as FDA Finds Deficiencies in Nuplazid sNDA
by Zacks Equity Research
The FDA identifies deficiencies in ACADIA's (ACAD) sNDA for Nuplazid (pimavanserin) for treating hallucinations and delusions associated with dementia-related psychosis. Stock sinks.
ACADIA (ACAD) Beats on Q4 Earnings, Misses on Revenues
by Zacks Equity Research
ACADIA's (ACAD) loss narrows in the fourth quarter of 2020 while it misses estimates for revenues. Nuplazid drives year-over-year revenues.
Acadia Pharmaceuticals (ACAD) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Acadia (ACAD) delivered earnings and revenue surprises of 12.50% and -1.52%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Acadia Pharmaceuticals (ACAD) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CRISPR (CRSP) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On CRISPR Therapeutics' (CRSP) fourth-quarter earnings call, investor focus will be on the company's progress with the development of its lead gene-editing candidate, CTX001.
Why Is Acadia (ACAD) Up 9.7% Since Last Earnings Report?
by Zacks Equity Research
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ACADIA (ACAD) Q3 Earnings Miss, Nuplazid Drives Revenues Y/Y
by Zacks Equity Research
ACADIA's (ACAD) earnings fall shy of estimates in the third quarter while revenues beat the same. The company maintains its net sales guidance for Nuplazid. Stock dips in after-hours trading.
Acadia Pharmaceuticals (ACAD) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Acadia (ACAD) delivered earnings and revenue surprises of -42.11% and 1.52%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
5 Drug/Biotech Stocks Set to Outpace Q3 Earnings Estimates
by Kinjel Shah
Let us take a look at some drug/biotech stocks that are poised to beat on third-quarter earnings.
TEVA Gears Up to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
On Teva's (TEVA) third-quarter conference call, investors will look for updates on the extent to which the coronavirus pandemic may have impacted sales of its products.
Humana (HUM) Gears Up for Q3 Earnings: What Awaits the Stock?
by Zacks Equity Research
Humana's (HUM) third-quarter 2020 results are likely to reflect elevated expenses and lower net investment income, partially offset by a growing membership base.
Earnings Preview: Acadia Pharmaceuticals (ACAD) Q3 Earnings Expected to Decline
by Zacks Equity Research
Acadia (ACAD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Acadia (ACAD) Down 12% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ACADIA Acquires CerSci Therapeutics to Boost Pain Portfolio
by Zacks Equity Research
ACADIA (ACAD) purchases CerSci Therapeutics and in turn, secures the global rights to a suite of novel compounds for neurological disorders comprising non-opioid therapies for acute and chronic pain.
ACADIA (ACAD) Q2 Earnings Surpass, Nuplazid Drives Sales
by Zacks Equity Research
ACADIA (ACAD) beats on earnings and revenues for the second quarter. The company lifts the lower end of its net sales view for Nuplazid, driving the stock in pre-market trading.
Acadia Pharmaceuticals (ACAD) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Acadia (ACAD) delivered earnings and revenue surprises of 38.64% and 4.22%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zomedica (ZOM) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Zomedica (ZOM) will provide an update on Truforma, its inaugural point-of-care diagnostic biosensor platform, when it reports second-quarter 2020 results
Drug/Biotech Stock Q2 Earnings on Aug 5: REGN, MRNA & More
by Kinjel Shah
Let us take a look at five drug/biotech companies, REGN, MRNA, SRPT, ACAD and HZNP, which are gearing up for their earnings release.
Aytu (AYTU) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Aytu (AYTU) will provide financial updates when it reports fourth-quarter fiscal 2020 results.